An orphan drug can cost up to $500,000 per year, far more than an average person can afford on their salary or hourly wage. Nonetheless, people need treatments for their life-threatening genetic diseases. So where does the money come from?
That point has been a major sticking point as the pharma industry starts to shift their research into increasing numbers of orphan drugs. While this has been a boon for rare disease patients, it has been giving the payers – the Healthcare providers – lots to worry about. This eBook – a preview of “The Great Debate” feature at next year’s Orphan Drug Congress, compiles arguments from both the capital markets/pharma and the payers, in their own words from interviews with our team, focusing on the most important points of contention.
What is covered in the book:
- See both sides of the argument from stakeholders
- Hear from capital markets and payers in their own words about where the industry is headed
- Get a preview of the debate that will be taking place at the World Orphan Drug Congress USA 2015
- Arm yourself with the arguments of the high-level executives in the Orphan Drug field for your side of the debate
This eBook is a preview to “The Great Debate” feature, which will be taking place at the 5th World Orphan Drug Congress USA on April 23-24, 2015.